References
- Gnecchi M, Zhang Z, Ni A, Dzau VJ. Paracrine mechanisms in adult stem cell signaling and therapy. Circ. Res.103, 1204–1219 (2008).
- Hegewald AA, Ringe J, Sittinger M, Thome C. Regenerative treatment strategies in spinal surgery. Front. Biosci.13, 1507–1525 (2008).
- Caplan AI. Why are MSCs therapeutic? New data: new insight. J. Pathol.217, 318–324 (2009).
- Brévignon-Dodin L. ATMP in practice: towards a new industry landscape in tissue engineering. J. Comm. Biotechnol.15, 59–65 (2009).
- Hughes-Wilson W, Mackay D. European approval system for advanced therapies: good news for patients and innovators alike. Reg. Med.2, 5–6 (2007).
Websites
- Europabio position paper on the proposal for a community regulatory framework on advanced therapies. www.europabio.org/positions/CRF-AdvTherapies.pdf (Accessed 20 January 2009)
- Moore R. hTEPs: The Regulatory Challenge. www.medicaldevice-network.com/features/feature136/ (Accessed 20 January 2009)
- Pyenson B, Murphy-Barron C. Realizing the Value of FDA-Approved Therapies. www.bio.org/healthcare/value/MillimanReport.asp (Accessed 20 January 2009)